All productsRetatrutide (Reta)
Size
- 10 mg — $80.00 CAD — Available
- 20 mg — $100.00 CAD — Available
- 30 mg — $130.00 CAD — Available
Research focus
A GIP, GLP-1 and glucagon receptor agonist studied in metabolic and body-weight research.
In simple words
Retatrutide is a research peptide that acts on GIP, GLP-1 and glucagon receptors. Researchers study these three hormone-signalling pathways in relation to metabolism and body weight.
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
Research references
Reviewed 2026-10-26
Human — randomized controlled trial
338 adults with obesity or overweight and a related condition.
The trial studied a GIP, GLP-1 and glucagon receptor agonist and reported greater weight reduction than placebo over 48 weeks.
Gastrointestinal adverse events and increases in heart rate occurred. Findings concern the trial formulation, not this vial, and do not establish long-term safety.
PMID 37366315. Indexed abstract checked through Europe PMC on 2026-10-26. Selected evidence, not a systematic review.
Resources
Identity search; no unambiguous compound record assigned to this listing. Check forms and synonyms carefully.
PubChemMechanism and target search. Automated access returned 403; DrugBank was not used to substantiate claims or approval status.
DrugBankProtein/precursor search, not a record of the supplied vial. Synthetic compounds and lab supplies may have no matching protein entry.
UniProtBioactivity search. Assay results depend on the tested compound, target and experimental conditions.
ChEMBLExplore indexed literature. Search results are not supporting citations; selected verified publications appear above.
PubMedExplore registrations. A match or completed study does not establish efficacy, approval or relevance to this vial.
ClinicalTrials.govReviewed human GLP1R record verified via UniProt API. This is a receptor record, not compound identity or evidence of vial activity.
UniProt — human GLP-1 receptorEvidence on studied compounds does not establish the identity, purity, safety, or regulatory approval of the catalogue vial. No Canadian regulatory status is assessed here.
Research questions about Retatrutide (Reta)
What is Retatrutide (Reta)?
Retatrutide is a research peptide that acts on GIP, GLP-1 and glucagon receptors. Researchers study these three hormone-signalling pathways in relation to metabolism and body weight.
What types of research are cited for Retatrutide (Reta)?
The Retatrutide (Reta) profile contains the following selected evidence. This is not a systematic review or a complete inventory of research.
Retatrutide: phase 2 obesity trial (2023): Human — randomized controlled trial
Publication: Retatrutide: phase 2 obesity trialWho or what was studied in the selected Retatrutide (Reta) references?
Retatrutide: phase 2 obesity trial (2023): 338 adults with obesity or overweight and a related condition.
Publication: Retatrutide: phase 2 obesity trialWhat identity distinctions matter for Retatrutide (Reta)?
The named research compound is described here; the identity and formulation of this catalogue vial have not been independently verified.
What do the selected Retatrutide (Reta) studies not establish?
Retatrutide: phase 2 obesity trial (2023): Gastrointestinal adverse events and increases in heart rate occurred. Findings concern the trial formulation, not this vial, and do not establish long-term safety.
Publication: Retatrutide: phase 2 obesity trialThese studies do not establish the identity, purity, safety or effects of the MXC Retatrutide (Reta) vial. Findings in one formulation, population or experimental model should not be assumed to apply to another.